Yi Ming48 developed a drug YM101 that blocks the TGF-β signaling pathway, which can convert cold tumors into hot tumors, increase the number of tumor-infiltrating lymphocytes and enhance antitumor immune responses in the TME, contributing to better antitumor effects. This evidence concerns the gene TGFB1 and neoplasm.